Experimental Polymerase Inhibitor Lowers HCV Viral Load Fast | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Early HCV Study Outcome: PSI-7977

Back to News Homepage
Next

Get The Facts About Hepatitis C Viral Load

Experimental Polymerase Inhibitor Lowers HCV Viral Load Fast

The Editors at Hepatitis Central
April 19, 2010

Print this page

After just three days of a Phase 1b trial, Vertex’s VX-222 is asserting itself as a possible contender to partner with telaprevir for a new Hepatitis C combination therapy regimen.

Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days In Phase 1b Trial

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus (HCV) polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

Continue reading this entire article:
http://www.thestreet.com/story/10726924/1/hepatitis-c-virus-polymerase-inhibitor-vx-222-reduced-viral-levels-over-three-days-in-phase-1b-trial.html?cm_ven=GOOGLEFI

No Comments - be the first!
Share
Share
Previous

Early HCV Study Outcome: PSI-7977

Back to News Homepage
Next

Get The Facts About Hepatitis C Viral Load

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.